Principal Financial Group Inc. Grows Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Principal Financial Group Inc. increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNXFree Report) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 238,350 shares of the biotechnology company’s stock after purchasing an additional 7,977 shares during the quarter. Principal Financial Group Inc. owned 0.54% of REGENXBIO worth $3,923,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of RGNX. Captrust Financial Advisors lifted its holdings in REGENXBIO by 742.1% in the first quarter. Captrust Financial Advisors now owns 960 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 846 shares during the period. Royal Bank of Canada lifted its holdings in REGENXBIO by 189.8% in the third quarter. Royal Bank of Canada now owns 1,397 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 915 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in REGENXBIO in the fourth quarter valued at approximately $38,000. PNC Financial Services Group Inc. lifted its holdings in REGENXBIO by 103.6% in the second quarter. PNC Financial Services Group Inc. now owns 1,963 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 999 shares during the period. Finally, Headlands Technologies LLC acquired a new position in REGENXBIO in the second quarter valued at approximately $44,000. Institutional investors and hedge funds own 88.80% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Stifel Nicolaus assumed coverage on REGENXBIO in a report on Wednesday, November 1st. They issued a “buy” rating and a $35.00 price target for the company. William Blair reissued a “neutral” rating and issued a $21.00 price target (up from $20.00) on shares of REGENXBIO in a report on Tuesday, November 14th. Finally, Wedbush reaffirmed a “neutral” rating and set a $21.00 target price on shares of REGENXBIO in a research note on Wednesday, January 17th. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.71.

Get Our Latest Analysis on RGNX

REGENXBIO Price Performance

Shares of RGNX stock opened at $14.57 on Thursday. The company has a market cap of $640.93 million, a price-to-earnings ratio of -2.44 and a beta of 1.20. The stock has a 50 day simple moving average of $16.59 and a 200-day simple moving average of $17.10. REGENXBIO Inc. has a 1-year low of $11.83 and a 1-year high of $25.32.

REGENXBIO (NASDAQ:RGNXGet Free Report) last posted its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($1.41) EPS for the quarter, beating the consensus estimate of ($1.44) by $0.03. REGENXBIO had a negative return on equity of 59.54% and a negative net margin of 262.18%. The firm had revenue of $28.90 million during the quarter, compared to the consensus estimate of $26.14 million. During the same period in the prior year, the company earned ($1.75) EPS. The firm’s revenue was up 9.1% compared to the same quarter last year. Analysts anticipate that REGENXBIO Inc. will post -4.99 earnings per share for the current fiscal year.

Insider Activity at REGENXBIO

In related news, insider Steve Pakola sold 17,237 shares of the stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $17.39, for a total value of $299,751.43. Following the completion of the transaction, the insider now directly owns 107,192 shares of the company’s stock, valued at approximately $1,864,068.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other REGENXBIO news, CEO Kenneth T. Mills sold 45,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $15.18, for a total value of $683,100.00. Following the completion of the sale, the chief executive officer now directly owns 408,035 shares in the company, valued at approximately $6,193,971.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Steve Pakola sold 17,237 shares of the company’s stock in a transaction on Wednesday, January 3rd. The shares were sold at an average price of $17.39, for a total value of $299,751.43. Following the completion of the sale, the insider now owns 107,192 shares of the company’s stock, valued at $1,864,068.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,237 shares of company stock valued at $1,868,451. 13.60% of the stock is owned by insiders.

About REGENXBIO

(Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Featured Stories

Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.